LA
BMRN icon

LBP AM’s BioMarin Pharmaceuticals BMRN Stock Holding History

LBP AM’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$220K Buy
3,839
+245
+7% +$13.4K ﹤0.01% 419
2026
Q1 		$203K Buy
+3,594
New +$210K ﹤0.01% 387
2025
Q4 		– Sell
-11,081
Closed -$600K – 415
2025
Q3 		$600K Sell
11,081
-278
-2% -$15.9K 0.01% 359
2025
Q2 		$624K Sell
11,359
-666
-6% -$39.2K 0.01% 345
2025
Q1 		$850K Buy
12,025
+6,576
+121% +$442K 0.01% 329
2024
Q4 		$358K Sell
5,449
-11,237
-67% -$753K ﹤0.01% 349
2024
Q3 		$1.17M Buy
16,686
+5,517
+49% +$461K 0.02% 282
2024
Q2 		$920K Buy
11,169
+1,117
+11% +$93K 0.04% 264
2024
Q1 		$878K Sell
10,052
-225,450
-96% -$20.2M 0.04% 269
2023
Q4 		$22.7M Hold
235,502
– – 0.5% 52
2023
Q3 		$20.8M Sell
235,502
-732
-0.3% -$65.1K 0.46% 59
2023
Q2 		$20.5M Buy
236,234
+11,605
+5% +$1.09M 0.48% 63
2023
Q1 		$21.8M Sell
224,629
-29,544
-12% -$3.06M 0.56% 59
2022
Q4 		$26.3M Buy
+254,173
New +$23.9M 0.75% 36

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

LBP AM's BMRN Position: Q2 2026 in Review

LBP AM increased its BioMarin Pharmaceuticals (BMRN) stake by 6.8% in Q2 2026, buying an estimated $13.4K and bringing the position to 3,839 shares worth $220K. The position accounts for ﹤0.01% of the portfolio, ranked #419.

LBP AM first reported a position in BMRN in Q4 2022 and has held it in 14 quarters since. The position peaked at $26.3M in Q4 2022. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • LBP AM held 3,839 shares of BioMarin Pharmaceuticals worth $220K as of Q2 2026.
  • LBP AM bought 245 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $13.4K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of LBP AM's portfolio in Q2 2026, its #419 holding.
  • LBP AM first reported a position in BioMarin Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • LBP AM's BioMarin Pharmaceuticals position peaked at $26.3M in Q4 2022.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on LBP AM's 13F filing for Q2 2026, filed 24 Jul 2026.